{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:04:58Z","timestamp":1787799898932,"version":"build-2784847793"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T00:00:00Z","timestamp":1332460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Laryngoscope"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives\/Hypothesis:<\/jats:title><jats:p>To evaluate the efficacy and safety of bevacizumab administered at a concentration of 50 mg as an intranasal spray in the treatment of epistaxis in patients suffering from Rendu\u2010Osler disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design:<\/jats:title><jats:p>Prospective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A preliminary, prospective, review board\u2010approved study was conducted on six patients with Rendu\u2010Osler disease who received 10 treatment courses of 50 mg bevacizumab. Monthly follow\u2010up was based on the epistaxis severity score (ESS), with adverse effects being reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Ten treatment courses were administered to six patients, with a mean follow\u2010up period of 2.8 months. A statistically significant decrease in mean ESS was observed at 1 month (<jats:italic>P<\/jats:italic> &lt; .001) and 2 months (<jats:italic>P<\/jats:italic> &lt; .005), whereas a nonsignificant decrease was found at 3 months (<jats:italic>P<\/jats:italic> = .07). A nonsignificant decline in mean ESS was detected at 1 month in patients with ESS \u22657 at baseline. No adverse effects were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The intranasal spray application of 50 mg bevacizumab was found to be an effective symptomatic treatment over a period of 2 months for patients with a pretreatment ESS of &lt;7, with no adverse effects being noted.<\/jats:p><\/jats:sec>","DOI":"10.1002\/lary.23230","type":"journal-article","created":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T06:20:28Z","timestamp":1328077228000},"page":"953-955","source":"Crossref","is-referenced-by-count":26,"title":["Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with rendu\u2010osler disease"],"prefix":"10.1002","volume":"122","author":[{"given":"Romain","family":"Guldmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Dupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Nivoix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Debry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.10002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510053331407"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001060100537"},{"key":"e_1_2_6_5_2","first-page":"591","article-title":"Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia","volume":"15","author":"Sadick H","year":"2005","journal-title":"Int J Mol Med"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0147-8"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/187221312798889284"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.07.023"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21415"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21345"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20818"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215100136369"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20159"},{"key":"e_1_2_6_15_2","article-title":"Ex vivo study of bevacizumab transport through porcine nasal mucosa","author":"Samson G","journal-title":"Eur J Pharm Biopharm"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flary.23230","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.23230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T06:29:23Z","timestamp":1700548163000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lary.23230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,23]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/lary.23230"],"URL":"https:\/\/doi.org\/10.1002\/lary.23230","archive":["Portico"],"relation":{},"ISSN":["0023-852X","1531-4995"],"issn-type":[{"value":"0023-852X","type":"print"},{"value":"1531-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,23]]}}}